ClinVar Miner

Submissions for variant NM_000020.2(ACVRL1):c.1121G>A (p.Arg374Gln) (rs1060503248)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000506001 SCV000602407 pathogenic not provided 2017-11-29 criteria provided, single submitter clinical testing The ACVRL1 c.1121G>A; p.Arg374Gln variant has been reported in the literature in individuals with hereditary hemorrhagic telangiectasia (HHT) (Abdalla 2003, Harrison 2003, McDonald 2011), and shown to have defective BMP9 ligand signaling (Ricard 2010). This variant has been reported to ClinVar (Variation ID: 411314), and is absent from the general population databases (Exome Variant Server, Genome Aggregation Database). The arginine at codon 374 is highly conserved across species, and computational algorithms (SIFT, PolyPhen2, MutationTaster) predict this variant to be damaging to the protein. Taken together, this variant is considered pathogenic. REFERENCES Link to ClinVar database for p.Arg374Gln: https://www.ncbi.nlm.nih.gov/clinvar/variation/411314/ Abdalla SA et al. Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum Genet. 2003 Apr;11(4):279-87. Harrison RE et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet. 2003 Dec;40(12):865-71. McDonald J et al. Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet. 2011 Apr;79(4):335-44. Ricard N et al. Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood. 2010 Sep 2;116(9):1604-12.
Invitae RCV000467491 SCV000552416 pathogenic Hereditary hemorrhagic telangiectasia type 2 2018-12-03 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 374 of the ACVRL1 protein (p.Arg374Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is not present in population databases (ExAC no frequency). This variant has been reported in several individuals affected with hereditary hemorrhagic telangiectasia and has been described to segregate with the disease in at least one family (PMID: 12700602, 18285823, 21158752, 25970827). ClinVar contains an entry for this variant (Variation ID: 411314). A different missense substitution at this codon (p.Arg374Trp) has been determined to be pathogenic (PMID: 12700602, 15517393, 17384219, 20501893). This suggests that the arginine residue is critical for ACVRL1 protein function and that other missense substitutions at this position may also be pathogenic. Experimental studies have shown that this missense change reduces ACVRL1 kinase activity (PMID: 20501893). For these reasons, this variant has been classified as Pathogenic.
Medical & Molecular Genetics Group,University of Lincoln RCV000488746 SCV000576331 pathogenic Pulmonary arterial hypertension related to hereditary hemorrhagic telangiectasia no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.